Home  »  Market Insights   »  Jaguar Health Inc. (JAGX) Stock Surges Ahead of Ap...

Jaguar Health Inc. (JAGX) Stock Surges Ahead of Approval for Merger with Dragon SPAC

Jaguar Health Inc. (JAGX) stock prices surged by 9.39% some time after market trading commenced on October 22nd 2021. This brought the price per share up to USD$1.98 early on in the trading day.

Do You Own These 7 Inflation-Survival Stocks?

Inflation is still near 40-year highs and rising prices are putting a big dent in our wallets. Unless you find out how to protect your portfolio and outpace inflation, you'll keep being at the mercy of economic factors out of your control. Especially since the price of electricity, food, and shelter are creeping up higher than ever. In this special report, I detail 7 stocks to help you survive and thrive in today's market. They're backed by solid companies, positioned to profit during tough economic times, and offer out-sized dividends to help you outpace inflation.

Click here to get your free copy of the report

Sponsored

Approval for Merger

October 25th 2021 saw JAGX stock announce the completion of the legally required Golden Powers process, which is legally required. The Golden Powers process was implemented by the Italian government as a response to the ongoing coronavirus pandemic. It is aimed at pharmaceutical transactions with foreign participation, in this case resulting in the company’s merger with Napo EU S.p.A. and Dragon SPAC S.p.A. to be effective within the next week. Following the Italian governments clearance for the merger, the combined entity will have the exclusive license agreement with Jaguar to the Crofelemer pipeline in Europe. This requires typical up-front license fees, milestone payments, royalties, and a drug supply agreement.

Synergistic Collaboration

JAGX stock also holds a substantial majority equity interest in the combined entity, which will keep the name Nap EU S.p.A. The company forecasts Napo EU to be listed on the European exchange. September 15th, 2021 saw the European Medicines Agency confirm the receipt of the Orphan Drug Designation application for Crofelemer for short bowel syndrome (SBS). The treatment has been granted the Orphan Drug Designation by the United States Food and Drug Administration. Napo EU’s starting efforts will be geared towards the conditional marketing authorization pathway for the EMA for Crofelemer in SBS with intestinal failure.

About JAGX Stock

The commercial stage pharmaceutical company aims to develop innovative, plant-based, non-opioid, and sustainable derived prescription medicines. These treatments are geared towards GI distress, with a particular focus on chronic, debilitating diarrhea. JAGX stock’s wholly owned subsidiary, Napo Pharmaceuticals, focuses on the development and commercialization of proprietary plant-based human gastrointestinal pharmaceuticals, which are made from plants harvested ethically from various rainforest areas. The company’s Mytesi product has been approved by the U.S. FDA for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.

Future Outlook for JAGX Stock

JAGX stock is poised to capitalize on the expanded scope of opportunities afforded to it as a result of the approved merger. The company is keen to maintain the momentum generated by this development in a bid to usher in unprecedented growth. Current and potential investors are hopeful that management will be able to leverage the resources at its disposal. This is hoped to facilitate significant and sustained increases in shareholder value over time.

Leave a Comment

Your email address will not be published. Required fields are marked *

Related Posts

385

SPECIAL GIFT

WE HAVE A GIFT FOR YOU

The 5 Best Inflation Stocks for 2022

100% free. stop anytime no spam

Get our free report on the stocks that we recommend for investors who want to protect their portfolios from inflation.

Receive Best Stock To Trade Before The Opening Bell

 

 

100% Free. Stop Anytime. No Spam